

Clare Bailey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8206115/publications.pdf>

Version: 2024-02-01

32
papers

990
citations

566801

15
h-index

476904

29
g-index

33
all docs

33
docs citations

33
times ranked

1254
citing authors

#	ARTICLE	IF	CITATIONS
1	Sustained Delivery Fluocinolone Acetonide Vitreous Implants. <i>Ophthalmology</i> , 2014, 121, 1892-1903.e3.	2.5	137
2	Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. <i>Eye</i> , 2020, 34, 1-51.	1.1	104
3	An observational study to assess if automated diabetic retinopathy image assessment software can replace one or more steps of manual imaging grading and to determine their cost-effectiveness. <i>Health Technology Assessment</i> , 2016, 20, 1-72.	1.3	88
4	The UK Diabetic Retinopathy Electronic Medical Record (UK DR EMR) Users Group, Report 2: real-world data for the impact of cataract surgery on diabetic macular oedema. <i>British Journal of Ophthalmology</i> , 2017, 101, 1673-1678.	2.1	65
5	Phase I Trial of Anti-Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology Retina</i> , 2017, 1, 474-485.	1.2	63
6	Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries. <i>British Journal of Ophthalmology</i> , 2019, 103, 1072-1077.	2.1	60
7	The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema. <i>British Journal of Ophthalmology</i> , 2017, 101, 75-80.	2.1	57
8	UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12. <i>British Journal of Ophthalmology</i> , 2015, 99, 1045-1050.	2.1	51
9	Intralesional Macular Atrophy in Anti-Vascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration in the IVAN Trial. <i>Ophthalmology</i> , 2019, 126, 75-86.	2.5	40
10	Previous Intravitreal Therapy Is Associated with Increased Risk of Posterior Capsule Rupture during Cataract Surgery. <i>Ophthalmology</i> , 2016, 123, 1252-1256.	2.5	39
11	UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice. <i>British Journal of Ophthalmology</i> , 2017, 101, 1683-1688.	2.1	37
12	The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group: Report 3: Baseline Retinopathy and Clinical Features Predict Progression of Diabetic Retinopathy. <i>American Journal of Ophthalmology</i> , 2017, 180, 64-71.	1.7	34
13	UK Age-Related Macular Degeneration Electronic Medical Record System (AMD EMR) Users Group Report IV. <i>Ophthalmology</i> , 2016, 123, 2386-2392.	2.5	31
14	Diabetic macular oedema and diode subthreshold micropulse laser (DIAMONDS): study protocol for a randomised controlled trial. <i>Trials</i> , 2019, 20, 122.	0.7	22
15	Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: the CENTERA Study. <i>American Journal of Ophthalmology</i> , 2021, 227, 106-115.	1.7	22
16	Extended real-world experience with the ILUVIEN® (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft® audit study. <i>Eye</i> , 2022, 36, 1012-1018.	1.1	18
17	Evaluation of a New Model of Care for People with Complications of Diabetic Retinopathy. <i>Ophthalmology</i> , 2021, 128, 561-573.	2.5	15
18	The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice. <i>Eye</i> , 2022, 36, 1725-1734.	1.1	14

#	ARTICLE	IF	CITATIONS
19	<p>Providing a Safe and Effective Intravitreal Treatment Service: Strategies for Service Delivery</p>. Clinical Ophthalmology, 2020, Volume 14, 1315-1328.	0.9	11
20	Health-related quality of life, visual function and treatment satisfaction following intravitreal dexamethasone implant for diabetic macular edema. Patient Preference and Adherence, 2017, Volume 11, 579-586.	0.8	10
21	Low-Level Nighttime Light Therapy for Age-Related Macular Degeneration: A Randomized Clinical Trial. , 2018, 59, 4531.		10
22	Prevalence and incidence of diabetic retinopathy (DR) in the UK population of Gloucestershire. Acta Ophthalmologica, 2022, 100, .	0.6	10
23	Conversion of Central Subfield Thickness Measurements of Diabetic Macular Edema Across Cirrus and Spectralis Optical Coherence Tomography Instruments. Translational Vision Science and Technology, 2021, 10, 34.	1.1	9
24	VISUAL ACUITY IMPROVEMENT WHEN SWITCHING FROM RANIBIZUMAB TO AFLIBERCEPT IS NOT SUSTAINED. Retina, 2018, 38, 951-956.	1.0	8
25	Prevalence and phenotype associations of complement factor I mutations in geographic atrophy. Human Mutation, 2021, 42, 1139-1152.	1.1	8
26	Phase IIb clinical trial of ranibizumab for the treatment of uveitic and idiopathic choroidal neovascular membranes. British Journal of Ophthalmology, 2016, 100, 1221-1226.	2.1	6
27	An Evaluation of a Battery of Functional and Structural Tests as Predictors of Likely Risk of Progression of Age-Related Macular Degeneration. , 2019, 60, 580.		6
28	Tumefactive demyelination presenting during bevacizumab treatment. BMJ Case Reports, 2015, 2015, bcr2015212173.	0.2	5
29	Epidemiology of moderately severe and severe non-proliferative diabetic retinopathy in South West England. Eye, 2021, , .	1.1	2
30	Multimodal imaging interpreted by graders to detect re-activation of diabetic eye disease in previously treated patients: the EMERALD diagnostic accuracy study. Health Technology Assessment, 2021, 25, 1-104.	1.3	1
31	Reply. Ophthalmology, 2019, 126, e72-e73.	2.5	0
32	Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL). Practical Neurology, 2021, 21, 448-451.	0.5	0